CSL Behring GmbH, Octapharma AG, and Kedrion S.p.A, among others, are the major players in the global market for prothrombin complex concentrate (PCC).
As per the analysis by Expert Market Research, the global prothrombin complex concentrate (PCC) market is expected to grow at a CAGR of about 9% in the forecast period of 2022-2027, owing to the clinical advantages it offers over fresh frozen plasma.
A large increase in PCC demand is anticipated due to its therapeutic superiority over fresh frozen plasma (FPP). PCC is more efficient than FFP and requires less volume and infusion time. Warfarin, a common Vitamin K antagonist, is also anticipated to contribute significantly to prothrombin complex concentrate (PCC) market expansion. The number of haemophilic patients worldwide is anticipated to rise in the coming years. PCC is necessary for their treatment, which will increase demand even further. With the easing of its usage approval, current government initiatives have also benefited the PCC market. The use of PCC for bleeding control has also been encouraged by government funding.
North America and Europe are considered to be the leading regions for prothrombin complex concentrate. Due to the advantages prothrombin complex concentrate has over fresh frozen plasma, the industry is booming and is expected to grow in the forecast period. With the outbreak of novel coronavirus, there has been a massive increase in the demand for prothrombin complex concentrate.
Since the United States’ Food and Drug Administration (FDA) has approved the use of Kcentra, the Asia Pacific region is also expected to give its approval and provide a push towards the prothrombin complex concentrate (PCC) market growth. Government funding has also promoted the use of prothrombin complex concentrate in the region.
Octapharma, in April 2021, announced that their study and research suggest the use of 4F-PCC as a replacement for fresh frozen plasma to treat bleeding during cardiac surgery. Based on the number of patients in the 4F-PCC group needing extra FP, the trial's main goals were to evaluate the viability of the protocol and the usefulness of 4F-PCC as a replacement for FP. Haemostatic effects and safety were secondary goals.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
|Headquarters:||Pennsylvania, United States|
CSL is a global leader in the field of biotechnology which uses latest technologies for saving lives. The company has a wide range of plasma-derived and recombinant therapies to offer. The company has its operations in more than 35 countries around the world. There are more than 270 plasma collection centres across China, Europe, and North America owned by the company. They also keep innovating and delivering life-saving medicines for patients that suffer from rare diseases.
The largest privately held and independent plasma fractionator is Octapharma, an international healthcare organisation. The three therapeutic fields of haematology, immunotherapy, and critical care are where the company primarily focuses its attention. It is regarded as one of the biggest producers of products containing human protein. The company also develops and produces medications using human proteins derived from human cell lines and human plasma. The company has six state-of-the-art factories, seven centres for research and development, and more than 160 centres for plasma.
A multinational corporation called Kedrion gathers and fractionates blood plasma in order to create and market medicines made from plasma. These products are used in the treatment of serious diseases, disorders, conditions like haemophilia, and deficiencies in the immune system. The activities of the company are carried out through several companies and subsidiaries. Kedrion also provides services to external partners and collaborators worldwide, such as contract manufacturing, technology transfer, and biological safety centre services.
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.